Latest Information Update: 27 Feb 2015
At a glance
- Originator 4SC Discovery
- Developer Panoptes Pharma
- Class Small molecules
- Mechanism of Action Interferon gamma inhibitors; Interleukin-17 inhibitors; Virus replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Infectious conjunctivitis; Uveitis